---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-035208"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:54:02.650338+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tivic Health winds down ClearUP consumer biz; Q3 net loss $2.6M

## Summary
- Q3 revenue $146K (+16% YoY); gross loss $145K from $230K inventory reserve for ClearUP exit.
- Net loss $2.6M vs $1.4M in Q3 2024; operating expenses rose to $2.3M on biopharma costs.
- ClearUP wind down: $347K charge incurred, $20-50K more expected; minimal revenue until approval.
- Transferred two INDs for Entolimod (neutropenia, cancer); cell line verification for cGMP completed.
- Cash $3.5M; $3.5M available via preferred equity; no debt.

## SEC filing metadata
- accession: 0001437749-25-035208
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/0001437749-25-035208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000143774925035208/tivc20250909_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-035208
- JSON: https://secwatch.observer/filing/0001437749-25-035208.json
- Plain text: https://secwatch.observer/filing/0001437749-25-035208.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.